Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation

In this work, heat stable dry powders of oxytocin (OT) suitable for delivery by oral inhalation were prepared. The OT dry powders were prepared by spray drying using excipients chosen to promote OT stability including trehalose, isoleucine, polyvinylpyrrolidone, citrate (sodium citrate and citric ac...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:AAPS PharmSciTech 2015-12, Vol.16 (6), p.1299-1306
Hauptverfasser: Fabio, Karine, Curley, Kieran, Guarneri, Joseph, Adamo, Benoit, Laurenzi, Brendan, Grant, Marshall, Offord, Robin, Kraft, Kelly, Leone-Bay, Andrea
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1306
container_issue 6
container_start_page 1299
container_title AAPS PharmSciTech
container_volume 16
creator Fabio, Karine
Curley, Kieran
Guarneri, Joseph
Adamo, Benoit
Laurenzi, Brendan
Grant, Marshall
Offord, Robin
Kraft, Kelly
Leone-Bay, Andrea
description In this work, heat stable dry powders of oxytocin (OT) suitable for delivery by oral inhalation were prepared. The OT dry powders were prepared by spray drying using excipients chosen to promote OT stability including trehalose, isoleucine, polyvinylpyrrolidone, citrate (sodium citrate and citric acid), and zinc salts (zinc chloride and zinc citrate). Characterization by laser diffraction indicated that the OT dry powders had a median particle size of 2 μm, making them suitable for delivery by inhalation. Aerodynamic performance upon discharge from proprietary dry powder inhalers was evaluated by Andersen cascade impaction (ACI) and in an anatomically correct airway (ACA) model, and confirmed that the powders had excellent aerodynamic performance, with respirable fractions up to 77% (ACI, 30 L/min). Physicochemical characterization demonstrated that the powders were amorphous (X-ray diffraction) with high glass transition temperature (modulated differential scanning calorimetry, MDSC), suggesting the potential for stabilization of the OT in a glassy amorphous matrix. OT assay and impurity profile were conducted by reverse phase HPLC and liquid chromatography-mass spectrometry (LC-MS) after storage up to 32 weeks at 40°C/75%RH. Analysis demonstrated that OT dry powders containing a mixture of citrate and zinc salts retained more than 90% of initial assay after 32 weeks storage and showed significant reduction in dimers and trisulfide formation (up to threefold reduction compared to control).
doi_str_mv 10.1208/s12249-015-0314-0
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4666249</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1787975827</sourcerecordid><originalsourceid>FETCH-LOGICAL-c545t-dbbe7469dfb599d449b14b17ac546092680e20f29c06d34c754fd3a2fdddf5103</originalsourceid><addsrcrecordid>eNqNkU9Lw0AQxRdRrFY_gBfJ0Ut0_2azF0HU2kKhgnpeNtlNm5Jm626i5tu7JbXUi3iagfebx8w8AC4QvEYYpjceYUxFDBGLIUE0hgfgBDECYyEIPtzrB-DU-yWEmCBBjsEAM84TkbITMB0b1cQvjcoqEz24Lnq2n9q4aPbVNTYv62hk3aqtVFPa2keFddGDqcoPE8isi2ZOVdGkXqgeOANHhaq8Od_WIXgbPb7ej-Pp7GlyfzeNc0ZZE-ssM5wmQhcZE0JTKjJEM8RVkBMocJJCg2GBRQ4TTWjOGS00UbjQWhcMQTIEt73vus1WRuembsIicu3KlXKdtKqUv5W6XMi5_ZA0SZLwsWBwtTVw9r01vpGr0uemqlRtbOsl4ikXnKWY_wMlaYpxSnBAUY_mznrvTLHbCEG5CUz2gckQmNwEJjenXO6fspv4SSgAuAd8kOq5cXJpW1eH9_7h-g30d6Fp</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1738822832</pqid></control><display><type>article</type><title>Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Springer Nature - Complete Springer Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Fabio, Karine ; Curley, Kieran ; Guarneri, Joseph ; Adamo, Benoit ; Laurenzi, Brendan ; Grant, Marshall ; Offord, Robin ; Kraft, Kelly ; Leone-Bay, Andrea</creator><creatorcontrib>Fabio, Karine ; Curley, Kieran ; Guarneri, Joseph ; Adamo, Benoit ; Laurenzi, Brendan ; Grant, Marshall ; Offord, Robin ; Kraft, Kelly ; Leone-Bay, Andrea</creatorcontrib><description>In this work, heat stable dry powders of oxytocin (OT) suitable for delivery by oral inhalation were prepared. The OT dry powders were prepared by spray drying using excipients chosen to promote OT stability including trehalose, isoleucine, polyvinylpyrrolidone, citrate (sodium citrate and citric acid), and zinc salts (zinc chloride and zinc citrate). Characterization by laser diffraction indicated that the OT dry powders had a median particle size of 2 μm, making them suitable for delivery by inhalation. Aerodynamic performance upon discharge from proprietary dry powder inhalers was evaluated by Andersen cascade impaction (ACI) and in an anatomically correct airway (ACA) model, and confirmed that the powders had excellent aerodynamic performance, with respirable fractions up to 77% (ACI, 30 L/min). Physicochemical characterization demonstrated that the powders were amorphous (X-ray diffraction) with high glass transition temperature (modulated differential scanning calorimetry, MDSC), suggesting the potential for stabilization of the OT in a glassy amorphous matrix. OT assay and impurity profile were conducted by reverse phase HPLC and liquid chromatography-mass spectrometry (LC-MS) after storage up to 32 weeks at 40°C/75%RH. Analysis demonstrated that OT dry powders containing a mixture of citrate and zinc salts retained more than 90% of initial assay after 32 weeks storage and showed significant reduction in dimers and trisulfide formation (up to threefold reduction compared to control).</description><identifier>ISSN: 1530-9932</identifier><identifier>EISSN: 1530-9932</identifier><identifier>DOI: 10.1208/s12249-015-0314-0</identifier><identifier>PMID: 25776985</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Administration, Inhalation ; Aerosols - chemistry ; Biochemistry ; Biomedical and Life Sciences ; Biomedicine ; Biotechnology ; Calorimetry, Differential Scanning - methods ; Chemistry, Pharmaceutical - methods ; Desiccation - methods ; Drug Compounding - methods ; Drug Stability ; Dry Powder Inhalers - methods ; Excipients - chemistry ; Hot Temperature ; Nanoparticles - chemistry ; Oxytocin - chemistry ; Particle Size ; Pharmacology/Toxicology ; Pharmacy ; Powders - chemistry ; Research Article ; Trehalose - chemistry ; X-Ray Diffraction - methods</subject><ispartof>AAPS PharmSciTech, 2015-12, Vol.16 (6), p.1299-1306</ispartof><rights>American Association of Pharmaceutical Scientists 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c545t-dbbe7469dfb599d449b14b17ac546092680e20f29c06d34c754fd3a2fdddf5103</citedby><cites>FETCH-LOGICAL-c545t-dbbe7469dfb599d449b14b17ac546092680e20f29c06d34c754fd3a2fdddf5103</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4666249/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4666249/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,41467,42536,51298,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25776985$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fabio, Karine</creatorcontrib><creatorcontrib>Curley, Kieran</creatorcontrib><creatorcontrib>Guarneri, Joseph</creatorcontrib><creatorcontrib>Adamo, Benoit</creatorcontrib><creatorcontrib>Laurenzi, Brendan</creatorcontrib><creatorcontrib>Grant, Marshall</creatorcontrib><creatorcontrib>Offord, Robin</creatorcontrib><creatorcontrib>Kraft, Kelly</creatorcontrib><creatorcontrib>Leone-Bay, Andrea</creatorcontrib><title>Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation</title><title>AAPS PharmSciTech</title><addtitle>AAPS PharmSciTech</addtitle><addtitle>AAPS PharmSciTech</addtitle><description>In this work, heat stable dry powders of oxytocin (OT) suitable for delivery by oral inhalation were prepared. The OT dry powders were prepared by spray drying using excipients chosen to promote OT stability including trehalose, isoleucine, polyvinylpyrrolidone, citrate (sodium citrate and citric acid), and zinc salts (zinc chloride and zinc citrate). Characterization by laser diffraction indicated that the OT dry powders had a median particle size of 2 μm, making them suitable for delivery by inhalation. Aerodynamic performance upon discharge from proprietary dry powder inhalers was evaluated by Andersen cascade impaction (ACI) and in an anatomically correct airway (ACA) model, and confirmed that the powders had excellent aerodynamic performance, with respirable fractions up to 77% (ACI, 30 L/min). Physicochemical characterization demonstrated that the powders were amorphous (X-ray diffraction) with high glass transition temperature (modulated differential scanning calorimetry, MDSC), suggesting the potential for stabilization of the OT in a glassy amorphous matrix. OT assay and impurity profile were conducted by reverse phase HPLC and liquid chromatography-mass spectrometry (LC-MS) after storage up to 32 weeks at 40°C/75%RH. Analysis demonstrated that OT dry powders containing a mixture of citrate and zinc salts retained more than 90% of initial assay after 32 weeks storage and showed significant reduction in dimers and trisulfide formation (up to threefold reduction compared to control).</description><subject>Administration, Inhalation</subject><subject>Aerosols - chemistry</subject><subject>Biochemistry</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Biotechnology</subject><subject>Calorimetry, Differential Scanning - methods</subject><subject>Chemistry, Pharmaceutical - methods</subject><subject>Desiccation - methods</subject><subject>Drug Compounding - methods</subject><subject>Drug Stability</subject><subject>Dry Powder Inhalers - methods</subject><subject>Excipients - chemistry</subject><subject>Hot Temperature</subject><subject>Nanoparticles - chemistry</subject><subject>Oxytocin - chemistry</subject><subject>Particle Size</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacy</subject><subject>Powders - chemistry</subject><subject>Research Article</subject><subject>Trehalose - chemistry</subject><subject>X-Ray Diffraction - methods</subject><issn>1530-9932</issn><issn>1530-9932</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU9Lw0AQxRdRrFY_gBfJ0Ut0_2azF0HU2kKhgnpeNtlNm5Jm626i5tu7JbXUi3iagfebx8w8AC4QvEYYpjceYUxFDBGLIUE0hgfgBDECYyEIPtzrB-DU-yWEmCBBjsEAM84TkbITMB0b1cQvjcoqEz24Lnq2n9q4aPbVNTYv62hk3aqtVFPa2keFddGDqcoPE8isi2ZOVdGkXqgeOANHhaq8Od_WIXgbPb7ej-Pp7GlyfzeNc0ZZE-ssM5wmQhcZE0JTKjJEM8RVkBMocJJCg2GBRQ4TTWjOGS00UbjQWhcMQTIEt73vus1WRuembsIicu3KlXKdtKqUv5W6XMi5_ZA0SZLwsWBwtTVw9r01vpGr0uemqlRtbOsl4ikXnKWY_wMlaYpxSnBAUY_mznrvTLHbCEG5CUz2gckQmNwEJjenXO6fspv4SSgAuAd8kOq5cXJpW1eH9_7h-g30d6Fp</recordid><startdate>20151201</startdate><enddate>20151201</enddate><creator>Fabio, Karine</creator><creator>Curley, Kieran</creator><creator>Guarneri, Joseph</creator><creator>Adamo, Benoit</creator><creator>Laurenzi, Brendan</creator><creator>Grant, Marshall</creator><creator>Offord, Robin</creator><creator>Kraft, Kelly</creator><creator>Leone-Bay, Andrea</creator><general>Springer US</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>5PM</scope></search><sort><creationdate>20151201</creationdate><title>Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation</title><author>Fabio, Karine ; Curley, Kieran ; Guarneri, Joseph ; Adamo, Benoit ; Laurenzi, Brendan ; Grant, Marshall ; Offord, Robin ; Kraft, Kelly ; Leone-Bay, Andrea</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c545t-dbbe7469dfb599d449b14b17ac546092680e20f29c06d34c754fd3a2fdddf5103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Administration, Inhalation</topic><topic>Aerosols - chemistry</topic><topic>Biochemistry</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Biotechnology</topic><topic>Calorimetry, Differential Scanning - methods</topic><topic>Chemistry, Pharmaceutical - methods</topic><topic>Desiccation - methods</topic><topic>Drug Compounding - methods</topic><topic>Drug Stability</topic><topic>Dry Powder Inhalers - methods</topic><topic>Excipients - chemistry</topic><topic>Hot Temperature</topic><topic>Nanoparticles - chemistry</topic><topic>Oxytocin - chemistry</topic><topic>Particle Size</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacy</topic><topic>Powders - chemistry</topic><topic>Research Article</topic><topic>Trehalose - chemistry</topic><topic>X-Ray Diffraction - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fabio, Karine</creatorcontrib><creatorcontrib>Curley, Kieran</creatorcontrib><creatorcontrib>Guarneri, Joseph</creatorcontrib><creatorcontrib>Adamo, Benoit</creatorcontrib><creatorcontrib>Laurenzi, Brendan</creatorcontrib><creatorcontrib>Grant, Marshall</creatorcontrib><creatorcontrib>Offord, Robin</creatorcontrib><creatorcontrib>Kraft, Kelly</creatorcontrib><creatorcontrib>Leone-Bay, Andrea</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>AAPS PharmSciTech</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fabio, Karine</au><au>Curley, Kieran</au><au>Guarneri, Joseph</au><au>Adamo, Benoit</au><au>Laurenzi, Brendan</au><au>Grant, Marshall</au><au>Offord, Robin</au><au>Kraft, Kelly</au><au>Leone-Bay, Andrea</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation</atitle><jtitle>AAPS PharmSciTech</jtitle><stitle>AAPS PharmSciTech</stitle><addtitle>AAPS PharmSciTech</addtitle><date>2015-12-01</date><risdate>2015</risdate><volume>16</volume><issue>6</issue><spage>1299</spage><epage>1306</epage><pages>1299-1306</pages><issn>1530-9932</issn><eissn>1530-9932</eissn><abstract>In this work, heat stable dry powders of oxytocin (OT) suitable for delivery by oral inhalation were prepared. The OT dry powders were prepared by spray drying using excipients chosen to promote OT stability including trehalose, isoleucine, polyvinylpyrrolidone, citrate (sodium citrate and citric acid), and zinc salts (zinc chloride and zinc citrate). Characterization by laser diffraction indicated that the OT dry powders had a median particle size of 2 μm, making them suitable for delivery by inhalation. Aerodynamic performance upon discharge from proprietary dry powder inhalers was evaluated by Andersen cascade impaction (ACI) and in an anatomically correct airway (ACA) model, and confirmed that the powders had excellent aerodynamic performance, with respirable fractions up to 77% (ACI, 30 L/min). Physicochemical characterization demonstrated that the powders were amorphous (X-ray diffraction) with high glass transition temperature (modulated differential scanning calorimetry, MDSC), suggesting the potential for stabilization of the OT in a glassy amorphous matrix. OT assay and impurity profile were conducted by reverse phase HPLC and liquid chromatography-mass spectrometry (LC-MS) after storage up to 32 weeks at 40°C/75%RH. Analysis demonstrated that OT dry powders containing a mixture of citrate and zinc salts retained more than 90% of initial assay after 32 weeks storage and showed significant reduction in dimers and trisulfide formation (up to threefold reduction compared to control).</abstract><cop>New York</cop><pub>Springer US</pub><pmid>25776985</pmid><doi>10.1208/s12249-015-0314-0</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1530-9932
ispartof AAPS PharmSciTech, 2015-12, Vol.16 (6), p.1299-1306
issn 1530-9932
1530-9932
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4666249
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Springer Nature - Complete Springer Journals; PubMed Central; Free Full-Text Journals in Chemistry
subjects Administration, Inhalation
Aerosols - chemistry
Biochemistry
Biomedical and Life Sciences
Biomedicine
Biotechnology
Calorimetry, Differential Scanning - methods
Chemistry, Pharmaceutical - methods
Desiccation - methods
Drug Compounding - methods
Drug Stability
Dry Powder Inhalers - methods
Excipients - chemistry
Hot Temperature
Nanoparticles - chemistry
Oxytocin - chemistry
Particle Size
Pharmacology/Toxicology
Pharmacy
Powders - chemistry
Research Article
Trehalose - chemistry
X-Ray Diffraction - methods
title Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T19%3A35%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Heat-Stable%20Dry%20Powder%20Oxytocin%20Formulations%20for%20Delivery%20by%20Oral%20Inhalation&rft.jtitle=AAPS%20PharmSciTech&rft.au=Fabio,%20Karine&rft.date=2015-12-01&rft.volume=16&rft.issue=6&rft.spage=1299&rft.epage=1306&rft.pages=1299-1306&rft.issn=1530-9932&rft.eissn=1530-9932&rft_id=info:doi/10.1208/s12249-015-0314-0&rft_dat=%3Cproquest_pubme%3E1787975827%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1738822832&rft_id=info:pmid/25776985&rfr_iscdi=true